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There is increasing evidence of the contribution of genetic susceptibility to the etiology of Parkinson’s disease (PD). Genetic
variations in the SNCA gene are well established by linkage and genome-wide association studies. Positive associations of single
nucleotide polymorphisms (SNPs) in SNCA and increased risk for PDwere found.However, the role of SNCAvariants in individual
traits or phenotypes of PD is unknown. Here, we reviewed the current literature and identified 57 studies, performed in fourteen
different countries, that investigated SNCA variants and susceptibility to PD. We discussed the findings based on environmental
factors, history of PD, clinical outcomes, and ethnicity. In conclusion, SNPs within the SNCA gene can modify the susceptibility
to PD, leading to increased or decreased risk. The risk associations of some SNPs varied among samples. Of notice, no studies in
South American or African populations were found. There is little information about the effects of these variants on particular
clinical aspects of PD, such as motor and nonmotor symptoms. Similarly, evidence of possible interactions between SNCA SNPs
and environmental factors or disease progression is scarce. There is a need to expand the clinical applicability of these data as well
as to investigate the role of SNCA SNPs in populations with different ethnic backgrounds.
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
that is characterized by motor dysfunction but also causes
nonmotor deficits [1]. Although the etiology of PD remains
unclear, the interaction between genetic and environmental
factors has been implicated in the emergence of the disease [2,
3]. Genome-wide association studies (GWAS) have identified
variants of many candidate genes that contribute to PD
susceptibility, such as variations of the SNCA gene [4–6].
Moreover, certain polymorphisms of SNCA are among the
major risk factors for sporadic PD [5].
The SNCA gene is located on human chromosome 4
and encodes the protein alpha-synuclein. The physiological
function of alpha-synuclein is not completely understood.
Studies have shown a key role for alpha-synuclein in the
regulation of neurotransmitter release, synaptic function, and
plasticity of dopaminergic neurons [7–9].The involvement in
dopaminergic transmission and the predominant presence of
alpha-synuclein in Lewy bodies [10–12] denote the relation-
ship of this protein with the etiology of PD. In addition,
genetic data support the role of alpha-synuclein in the
pathogenic process of the disease. For example, missense
mutations in SNCA locus were identified in familial forms
of PD (A53T, A30P, E46K, and H50Q) [13–17], as well as in
sporadic PD patients (A18T and A29S) [18]. Further, dupli-
cations and triplications of the SNCA locus cause familial
parkinsonism and correlate with disease severity [19, 20].
Single nucleotide polymorphism (SNP) analyses in case-
control studies performed in different populations have
shown an association between several SNCA polymorphisms
and the risk of PD. For example, the dinucleotide repeat
REP1 located in the SNCA promoter (SNCA-REP1) and
the 3󸀠 untranslated region (UTR) variants are frequently
investigated [21]. Variations in these regions may increase
susceptibility to PD by interfering with transcription factor
binding sites [22, 23] and creating or destroying microRNAs
target sites, which in turn modifies gene expression [24–26].
Hindawi
Parkinson’s Disease
Volume 2017, Article ID 4318416, 11 pages
https://doi.org/10.1155/2017/4318416
2 Parkinson’s Disease
In spite of the fact that this type of study is frequent,
investigations of the association between SNPs and the risk
of PD in different populations show conflicting results. Fur-
thermore, the consequences of genetic variability on clinical
phenotypes, as well the interaction between genetic and envi-
ronmental substrates, are poorly elucidated. Ideally, data from
SNP studies would improve knowledge of pathophysiological
pathways and help to target the best therapeutic program.
This review aims to identify and compare the main SNP
association studies conducted in different populations. The
role of SNCA polymorphisms as a risk factor for PD and their
association with clinical outcomes are discussed.
2. Literature Search
We conducted a survey in the relevant databases PubMed/
Medline and Scopus for studies up to July 2016 using combi-
nations of the keywords “polymorphism”, “alpha synuclein”,
“SNCA gene”, and “Parkinson’s disease”. We selected articles
that met the following inclusion criteria: (a) articles that are
written in English; (b) articles that described investigations
of SNPs in the SNCA gene; (c) articles that had available
data of allele and genotype distributions; (d) studies that
were conducted in humans; (e) studies including participants
who were diagnosed with Parkinson’s disease. 57 studies
were selected to conduct the review. In addition, despite
not necessarily meeting the selection criteria, other relevant
publications were included throughout the article in order to
foment discussion.
The following informationwas extracted fromeach study:
authors, year of publication, country of the studied popula-
tion, number of patients and control subjects, risk association
with PD, and investigation of environmental factors and
clinical outcomes. The association of SNCA polymorphisms
and PD susceptibility was often assessed by comparing the
frequency of risk allele and risk genotypes in patients and
controls. Values of odds ratio (OR) and confidence interval
(95% CI) indicated the characteristic and significance of the
association (OR values higher than 1 indicated increased risk
and values lower than 1 suggested reduced risk).
Table 1 summarizes the main data from the 57 selected
studies. The majority of the studies were performed in
Caucasian and Asian populations. The studies were carried
out in fourteen different countries (Mexico, China, Russia,
Germany, Taiwan, USA, Japan, Spain, Italy, Ireland, Nether-
lands, Norway, Australia, and Greece) assembling patients
from twenty countries (Mexico, China, Russia, Germany, Tai-
wan, USA, Japan, Spain, Italy, Norway, Netherlands, Serbia,
Ireland, Australia, France, Greece, Poland, Sweden, Iran, and
Australia). Sample sizes varied from 91 to 5302 patients in PD
groups. The mean age at onset of PD varied from 45.2 to 68.2
years old.
3. SNPs and the Risk for Parkinson’s Disease
GWAS have identified 28 distinct loci that modify the
individual risk to PD [85] and suggest that genetic factors
contribute to at least one-fourth of the total variation in
liability to PD [86].The twomost consistent genes for suscep-
tibility to sporadic PD are the alpha-synuclein (SNCA) and
microtubule-associated protein tau (MAPT) genes, which
can exert independent or joint effects on the risk of PD [56,
59, 61, 62, 87]. In addition, variants in other genes previously
linkedwith autosomal forms (LRRK2, PARK16–18, andGBA)
have also shown association with PD risk [64, 88–90]. Based
on odds ratio and confidence intervals values in the selected
studies, thirty-nine different SNPs in the SNCA gene showed
a statistically significant effect on PD susceptibility: nine
variants in the 5󸀠 end, nine variants near the 3󸀠 end, and
25 intron variants (Table 2). The locations of the six more
frequently investigated SNPs within the SNCA gene are
illustrated in Figure 1.
Two major linkage disequilibrium blocks in the SNCA
gene have been proposed: (1) a 5󸀠 block that extends from
the promoter-enhancer region to exon 4 and (2) a 3󸀠 block
that includes intron 4, 3󸀠 UTR, and the 3󸀠 end region of the
gene [73, 80]. SNPs in the 3󸀠 block presented a more expres-
sive association with PD. The largest number of significant
markers in the 3󸀠 block across different populations suggests a
major causal effect for variants located in the 3󸀠 end compared
with the 5󸀠 end. The 3󸀠 block contains elements with higher
conservation across species, which emphasize its biological
relevance [25].
The polymorphic microsatellite REP1 (D4S3481) in the
promoter region of SNCA is one of the most frequently
investigated polymorphisms and was pointed out as a risk
factor in thirteen of the articles [47, 50, 60, 64, 65, 68,
71–73, 75, 77, 79, 81]. REP1 region plays a crucial role
in the regulation of alpha-synuclein protein expression.
Variants in REP1 are the only putative functional polymor-
phism identified within the SNCA locus. The REP1 SNP
is a triallelic polymorphism with the longest (263 bp) and
intermediate length (261 bp) alleles usually associated with
an increased risk for PD, as seen in studies with North
American [47, 50, 60, 64, 65, 68, 71, 72, 75, 81], German [73],
Greek [79], and Dutch [77] samples. In 2006, a meta-analysis
including over 5000 subjects provided strong evidence that
the 263 bp allele was more frequent in cases and that the
259 bp allele was more frequent in controls (indicating
decreased risk of PD) [91]. The other four SNPs in the
5󸀠 region (rs2619362, rs2619363, rs2619364, and rs2583988)
contributed to the increase in the risk of PD in North
American [49, 65] and European [56, 61, 77] populations.
Twenty-five intronic variants were associated with PD
susceptibility, although the precise function of those variants
of human SNCA is still unknown. The SNP rs2736990 in
intron 4 was the most frequent, with the exception of one
study [40]; this SNP was a consistent risk factor for PD [27,
28, 41, 49, 52, 55]. Similarly, the SNPs rs2572324, rs7684318,
and rs894278 also increased susceptibility to sporadic PD
[49, 60, 64, 65]. In contrast, a significant reduction of PD
risk was found for the SNP rs356186 in Italian [56], North
American [60], and Irish [61] samples.
Recently, the SNPs located near the 3󸀠 end have also
been identified as risk factors for PD. Within the 3󸀠 region,
the majority of the studies focused on rs356219, rs11931074,
and rs356165. Among them, the SNP rs356219 was the most
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Table 1: Characterization of the reviewed studies.
Studies Study ID Country of participants Sample size Onset age
PD Ctr (mean ± SD)
Davila-Ortiz de Montellano et al., 2016 [27] Mexico 171 171 —
Davis et al., 2016 [28] USA 418 150 60.4 ± 11.1
Garc´ıa et al., 2016 [29] Mexico 106 135 56.2 ± 14.4
Shahmohammadibeni et al., 2016 [30] Iran 489 489 —
Wang et al., 2016 [31] China 296 — —
Cheng et al., 2016 [32] China 1053 1152 52.0 ± 10.4
Guella et al., 2016 [33] Multicentric∗ 1492 971 60.3 ± 10.2
Chen et al., 2015 [34] China 218 110 60.6 ± 07.4
Huang et al., 2015 [35] China, Australia 402 — —
Han et al., 2015 [36] China 91 92 —
Chen et al., 2015 [37] China 1276 846 56.3 ± 11.5
Gao et al., 2015 [38] USA 507 1330 68.3 ± 5.8
Cardo et al., 2014 [39] China 752 489 —
Guo et al., 2014 [40] China 1011 721 56.6 ± 11.8
Pan et al., 2013 [41] China 515 450 45.2 ± 04.6
Mata et al., 2014 [42] USA 1191 — 59.46 ± 10.6
Markopoulou et al., 2014 [43] USA 1098 — 62.2
Emelyanov et al., 2013 [44] Russia 244 308 —
Wu-Chou et al., 2013 [45] Taiwan 626 473 63.2 ± 07.8
Brockmann et al., 2013 [46] Germany 1396 — 56.9 ± 01.9
Chung et al., 2013 [47] USA 1098 1098 60.4
Pihlstrøm et al., 2013 [48] Norway and Sweden 1380 1295 59.0
Heckman et al., 2012 [49] USA 426 769 62.0 ± 12.0
Ritz et al., 2012 [50] USA 232 — —
Schmitt et al., 2012 [51] Germany 980 1005 59.4 ± 12.2
Miyake et al., 2012 [52] Japan 229 357 65.7 ± 08.8
Pan et al., 2012 [53] China 403 315 57.8 ± 08.6
Cardo et al., 2012 [54] Spain 727 480 —
Gao et al., 2012 [55] USA 584 1571 68.2 ± 05.7
Trotta et al., 2012 [56] Italy 904 891 56.1 ± 11.0
Hu et al., 2012 [57] China 110 136 56.7 ± 10.8
Botta-Orfilla et al., 2012 [58] Spain 84 — —
Mata et al., 2011 [59] Spain 1445 1161 60.0 ± 12.2
Chung et al., 2011 [60] USA 1103 1103 62.2
Elbaz et al., 2011 [61] Multicentric∗∗ 5302 4161 —
Wider er al., 2011 [62] USA, Ireland, Norway 1020 1095 58.0 ± 12.0
Botta-Orfilla et al., 2011 [63] Spain 757 708 —
Biernacka et al., 2011 [64] USA 1098 1098 62.2
Mata et al., 2010 [65] USA 1956 2112 58.7 ± 11.9
Yu et al., 2010 [66] China 332 300 54.3 ± 11.1
Hu et al., 2010 [67] China 330 300 52.6 ± 11.8
Gatto et al., 2010 [68] USA 333 336 —
Rajput et al., 2009 [69] Canada 452 245 —
Sutherland et al., 2009 [70] Australia 331 296 60.1 ± 10.6
Brighina et al., 2009 [71] USA 893 893 62.1
Kay et al., 2008 [72] USA 1802 2192 —
Myhre et al., 2008 [73] Netherlands 236 236 —
Verbaan et al., 2008 [74] Netherlands 295 150 —
Brighina et al., 2008 [75] USA 833 833 61.9
Ross et al., 2007 [76] Ireland 186 186 50.0 ± 11.0
Winkler et al., 2007 [77] Germany, Serbia 397 270 —
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Table 1: Continued.
Studies Study ID Country of participants Sample size Onset age
PD Ctr (mean ± SD)
Goris et al., 2007 [78] UK 659 2176 63.0
Hadjigeorgiou et al., 2006 [79] Greece 178 186 63.3 ± 9.6
Mueller et al., 2005 [80] Germany 669 1002 55.4 ± 19.1
Mamah et al., 2005 [81] USA 557 557 63.0
Spadafora et al., 2003 [82] Italy 186 182 —
Izumi et al., 2001 [83] Japan 200 250 61.0 ± 09.1
ID: identification; PD: Parkinson’s disease group; Ctr: control group; SD: standard deviation. ∗The countries of origin of participants were New Zeeland,
Canada, UK, and USA. ∗∗The countries of origin of participants were Australia, France, Germany, Greece, Ireland, Italy, Norway, Poland, Sweden, and USA.
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Figure 1: Diagram illustrating the locations of the main SNPs in human SNCA gene reviewed in the present study: SNCA-REP1 (promoter
region), rs2736990 (intron 4), rs356165 (3󸀠 UTR), and rs356219, rs356220, and rs11931074 (3󸀠 end). Black boxes indicate translated exons, grey
boxes indicate untranslated regions, and the white line indicates introns.
investigated, and it stands out as a consistent risk factor for
PD in twelve of the studies. Variants in the 3󸀠 region possibly
increase SNCA expression because of the misregulation of
the posttranscriptional control. In the 3󸀠 untranslated region
(UTR), there are target binding sites for two microRNAs
(mir-7 and mir-153), and alterations in these regions might
affect mRNA stability and translation [92]. Further, mir-7
and mir-153 were associated with SNCA mRNA expression
in human studies [23, 24].The SNP rs356219 showed a robust
association as a common susceptibility marker in twelve
studies with patients from Russia [44], Germany [46, 80],
Spain [58, 59], Japan [52], China [53], USA [28, 65], United
Kingdom [78], and Netherlands [73]. Similarly, the SNP
rs11931074 showed a significant association with increased
PD risk in seven studies, four of which were performed in
Chinese samples [32, 34, 39, 40].
The variants rs356221, rs356165, and rs356182 in 3󸀠 UTR
also contribute significantly to the increase in the PD risk in
Germany [51, 77, 80], USA [28, 50], China [34], Taiwan [45],
and Netherlands [73]. These findings reinforce the role of a
posttranscriptional mechanism in PD etiology. The variant
rs356165 was themost expressive [28, 50, 51, 54, 61, 73, 77, 80].
4. SNCA SNPs and Environmental
Factors Interactions
Despite the relevance of environmental data to the under-
standing of the etiology of PD, themajority of studies contain
little or no information on possible associations between
SNCA SNPs and environmental factors (Table 3).
Sporadic PD is considered a result of complex inter-
actions between genetic and environmental risk factors.
Professional pesticide exposure, rural living, and well-water
drinking were reported to increase the risk of PD [93–95]. In
contrast, cigarette smoking [96, 97] and caffeine intake [98]
have been pointed out as protective factors. Furthermore,
though less consistently, reduced PD risk was associated with
alcohol drinking [99]. Potential interactions between SNCA
SNPs and pesticide exposure, smoking habits, head injury, or
coffee and alcohol drinking were investigated in a few of the
studies [47, 50, 52, 55, 56]. Overall, data demonstrated some
pairwise interactions, but without reaching significant levels
after Bonferroni correction. For example, although Miyake
et al. [52], Chung et al. [47], and Gao et al. [55] found a
significant protective effect of smoking habits against PD,
corroborating epidemiological data, only the first study found
significant interactions between SNPs rs356219 and rs356220
and smoking.
Meta-analyses [96, 97] have reinforced the inverse asso-
ciation between cigarette smoking and PD risk more consis-
tently than other environmental factors (rural living, well-
water consumption, farming, and the use of pesticides). One
of the mechanisms suggested to underlie this neuroprotec-
tion is the reduction of brain levels of the enzymemonoamine
oxidase B (MAO B), an isoform that selectively metabo-
lizes dopamine. This reduction would enhance the levels of
dopamine and decrease the production of hydrogen peroxide
and oxidative stress rates [100]. An alternative explanation is
that smoke induces cytochrome P-450 enzyme activity. This
enzyme is responsible for the metabolism of antipsychotic
drugs and the detoxification of certain environmental toxins
such as MPTP [101]. In this respect, a case-control study
carried out in European countries investigated polymor-
phisms with relevance to brain expression and metabolism
Parkinson’s Disease 5
Table 2: Single nucleotide polymorphisms (SNPs) in SNCA associated with Parkinson’s disease.
Variant Region Alleles Studies∗ with significant association with PD risk
REP1 Promoter 259 bp/261 bp/263 bp [47, 50, 60, 64, 65, 68, 71–73, 75, 77, 79, 81] (↑) [43, 56, 76] (↓)
rs1372519 Promoter A/G [49] (↓)
rs2301134 Promoter C/T [45, 76] (↑)
rs2301135 Promoter C/G [45] (↓)
rs2619361 Promoter A/C [49] (↑)
rs2619362 5󸀠 region C/T [49] (↑)
rs2619363 5󸀠 region G/T [49, 77] (↑)
rs2619364 5󸀠 region A/G [66, 77] (↑)
rs2583988 5󸀠 region C/T [49, 56, 61, 77] (↑)
rs2119787 Intron A/G [65] (↓)
rs2197120 Intron A/G [56] (↓)
rs2572324 Intron C/T [49, 60, 64, 65] (↑)
rs2583959 Intron C/G [49, 64] (↑)
rs2736990 Intron T/C [27, 28, 41, 47, 49, 52, 55, 60] (↑) [40] (↓)
rs2737020 Intron C/T [76] (↓)
rs2737029 Intron C/T [56, 65, 80] (↑)
rs2737033 Intron A/G [46] (↑)
rs356164 Intron C/G [76] (↓)
rs356168 Intron A/G [64, 80] (↑)
rs356186 Intron A/G [56, 60, 76] (↓)
rs356203 Intron A/G [27, 80] (↑)
rs356204 Intron A/G [80] (↑)
rs3822086 Intron C/T [37] (↓)
rs3857057 Intron A/G [33] (↑)
rs3857059 Intron A/G [29, 80] (↑)
rs6848726 Intron C/T [80] (↓)
rs7684318 Intron C/T [27, 66] (↑)
rs7689942 Intron C/T [33] (↑)
rs894278 Intron G/T [35, 36] (↑)
rs1372520 Intron C/T [47, 49] (↑) [60] (↓)
rs10018362 Intron C/T [33] (↑)
rs2737012 Intron C/T [49] (↑)
rs3756063 Intron C/G [36] (↑)
rs3775423 Intron C/T [48, 60, 64] (↑)
rs356221 3󸀠 region A/T [45, 48, 77] (↑)
rs356165 3󸀠 region A/G [28, 50, 51, 54, 69, 73, 76, 77, 80] (↑)
rs356182 3󸀠 region A/G [32] (↑)
rs356218 3󸀠 region A/G [47, 49, 60] (↑)
rs356219 3󸀠 region A/G [28, 42, 44, 46, 52, 53, 59, 61–63, 65, 73, 78, 80] (↑)
rs356220 3󸀠 region C/T [27, 28, 30, 33, 52, 55, 80] (↑) [40] (↓)
rs356225 3󸀠 region C/T [33] (↑)
rs181489 3󸀠 region C/T [61, 76, 77] (↑)
rs11931074 3󸀠 region G/T [30, 31, 34, 39, 55, 57, 61] (↑) [37, 45] (↓)
SNP: single nucleotide polymorphism. ∗See Table 1. Arrows indicate whether the SNP increased (↑) or reduced (↓) PD susceptibility in each study, based on
values of odds ratio and confidence intervals.
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Table 3: Association of environmental factors of PD with SNPs in SNCA.
Environmental factors Studies∗ Results
Smoking [34, 38, 47, 50, 52, 55, 56, 68, 70]
Individuals with GG-rs356219 and TT-rs356220
genotypes [52] and carriers of allele REP1-263 bp [47]
who never had smoked had a significantly increased
risk of PD.
Coffee intake [38, 47, 55, 56] No SNPs were significantly associated with this factor.
Pesticide exposure [47, 68, 70, 71] Chung et al. [47] found a suggestive associationbetween C-rs3775423 and pesticide exposure.
Alcohol drinking [47, 75]
Brighina et al. [75] found independent effects to alcohol
consumption and REP1-SNCA. Alcohol use was
associated with a decreased PD risk.
Head injury [38]
Head injury increases PD risk, especially when it
happens before the age of 30; no significant association
with SNCA SNPs.
∗See Table 1.
Table 4: Association of clinical aspects of PD and SNPs within SNCA.
Variables Studies∗ Results
Age at onset [28, 32, 35, 37, 40, 41, 46, 53, 54, 58, 66,69, 70, 72, 79]
SNPs were associated with earlier PD onset:
REP1-263 bp [35, 69, 79]; C-rs2736990 [41]; G-rs894278
[35]; G-rs356219 [46, 53, 58]; G-rs356215 [54]
Motor outcomesa [28, 31, 32, 34, 43, 50, 51, 74]
Wang et al. [31] found a protective association between
T-rs11931074 allele carriers and motor severity. Ritz et
al. [50] found that REP1-263 bp and G-rs356165 alleles
increased the risk of faster decline of motor function,
whereas Markopoulou et al. [43] demonstrated that
REP1-263 bp allele reduced the risk of developing motor
impairments
Cognition outcomesb [31–34, 37, 40, 42, 43, 74, 78]
Markopoulou et al. [43] showed an increased risk of
cognitive impairment in carriers of REP1-259 bp allele.
Guella et al. [33] found a significant association of
C-rs10018362, T-rs7689942, and G-rs1348224 alleles
with PD with dementia
Anxiety and depressionc [32, 34, 37, 40, 74] No SNPs were significantly associated with symptoms
Autonomic and sleep
disordersd [34, 74] No SNPs were significantly associated with symptoms
Hyposmia [34, 74] In Chen et al.’s study [34], TT-rs11931074 genotypeincreased the risk of hyposmia in PD
∗See Table 1. aQuestionnaires used: Unified Parkinson Disease Rating Scale-III and Hoehn and Yahr. bQuestionnaires used: Mini-Mental State Examination,
Frontal Assessment Battery, Montreal Cognitive Assessment, Scales for Outcomes in Parkinson’s Disease Cognition, Hopkins Verbal Learning Test-Revised,
Letter-Number Sequencing Test and Trail Making Test, Semantic and Phonemic Verbal Fluency Tests, and Benton Judgment of Line Orientation test.
cQuestionnaires used: Hamilton Rating Scale for Depression andAnxiety and BeckDepression Inventory. dQuestionnaires used: REMSleep Behavior Disorder
Questionnaire, and Scales for Outcomes in Parkinson’s Disease Autonomic, Nighttime Sleep, Daytime Sleepiness and Psychiatric Complications.
of substances contained in tobacco smoke and confirmed
significant interactions of SNPs in cytochrome P-450 enzyme
family genes (GSTM1, GSTP1, and NAT2). However, there
is no information about the mechanisms that explain the
biological interaction between SNCA genotypes and cigarette
smoking.
5. SNCA SNPs and PD Clinical
Outcomes Interactions
The influence of polymorphisms on PD phenotypic variabil-
ity remains unclear. Indeed, few studies specifically investi-
gated their associations with particular aspects of the disease,
such as disease history and clinical outcomes (Table 4).
The age at onset is the most frequently investigated
and well established aspect of disease history. Polymor-
phisms located in the promoter (REP1), introns (rs2736990,
rs894278), and 3󸀠 region (rs356219 and rs356165) are sug-
gested to be predictors of earlier PD onset in Australian
and Chinese [35], Spanish [54], German [46], and UK [61]
samples.The identification of genetic features associated with
the onset of PD has a relevant potential for therapeutic target-
ing. In view of the fact that neurodegeneration precedes the
appearance of motor symptoms [102], it is critical to predict
the risk of developing PD prior to clinical manifestations.
Even though it is expected that SNCA variants would
influence individual traits or phenotypes of sporadic PD,
this association was poorly explored in the studies. In a
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Table 5: Interactions between alpha-synuclein levels and SNCA SNPs.
Study SNP Risk allele Results
Hu et al. [57]
rs11931074 T The allele was associated with reduced levels of alpha-synuclein inserum
REP1 Different alleles and genotypes did not influence levels ofalpha-synuclein in serum
Mata et al. [65] rs356219 C CC genotype was correlated with increased levels of alpha-synucleinin plasma
Fuchs et al. [84]a
rs2583988 T No correlation with alpha-synuclein mRNA or protein levels
REP1 261 pb 256 pb/256 bp genotype was associated with lower alpha-synucleinlevels assessed in blood samples; no effect in brain samples
rs356219 C
CT genotype correlated with higher SNCA mRNA levels in the
substantia nigra and TT genotype showed higher SNCA mRNA levels
in the cerebellum; no effect in blood samples
McCarthy et al. [24]a
rs2736990 G In the 3 SNPs, the GG genotype correlated with an increased
expression ratio of SNCA112 mRNA in the frontal cortexrs356165 G
rs356219 G
McCarthy et al. [24]a rs3857059 G No correlation between genotypes and the ratio expression levels ofSNCA112 mRNArs17016074 A
Cardo et al. [39]a rs356165rs11931074
G
T
No significant differences for the SNCA isoform levels between the
different genotypes assessed in brain tissues
aPostmortem studies.
longitudinal study with a North American sample, Ritz et al.
[50] showed that the REP1-263 bp promoter variant and the
G-rs356165 allele are risk factors to faster motor progression
in Caucasian and non-Caucasian PD patients (OR 1.66; 95%
CI: 0.96–2.88). Wang et al. [31] found a protective association
between T-rs11931074 allele and motor severity. However,
in a larger sample of Caucasian patients, Markopoulou et
al. [43] showed that REP1-263 pb allele reduced the risk of
developing motor impairments. This divergence can be a
result of differences in the methods of motor evaluation.
According to Markopoulou et al. [43], the discrepancies may
also suggest a dual and time-dependent role of SNCA.
Impairments in the olfactory function are a common
early-stage nonmotor feature of PD, and the TT-rs11931074
genotype may increase the risk of hyposmia in PD cases [34].
Few other studies pointed out weak or absent associations
with clinical outcomes such as anxiety or depression [32,
34, 37, 40, 74], sleep and autonomic disorders [34, 74], and
cognitive impairments [31, 32, 34, 37, 40, 74]. Regarding
cognitive features, Markopoulou et al. [43] demonstrated
that the REP1-259 pb allele increased the risk of cognitive
outcomes. Trotta et al. [56] found significant associations
of C-rs10018362, T-rs7689942, and G-rs1348224 alleles with
PD with dementia and also identified a specific haplotype in
intron 4 of SNCA (C-rs62306323 and T-rs7689942) associ-
ated with increased risk of PD with dementia. It is important
to mention that limited data of SNP associations with PD
phenotype in cross-sectional studies might be related to a
single event of clinical assessment, which couldmask possible
effects. Studies of such associations could provide important
clinical applicability of the significant findings of genotyping
studies. More studies evaluating specific clinical aspects,
especially with longitudinal designs, are necessary to enhance
the understanding of how genetic factors contribute to PD.
6. Biological Effects of SNCA SNPs
There is increasing evidence supporting the biological effects
of genetic variants in SNCA, possibly by modifying alpha-
synuclein expression. Among the studies listed in Table 5,
the associations of SNCA-REP1 and 3󸀠 variants (rs356219
and 11931074) and peripheral alpha-synuclein levels were
investigated in Chinese [57] and North American [65] popu-
lations. Mata et al. [65] found an association of CC-356219
genotype with increased plasma levels of alpha-synuclein.
A variation in the REP1 region might affect transcriptional
activity by increasing the expression of alpha-synuclein and
consequent protein accumulation [22, 23]. SNCA duplication
and triplication in familial PD have been linked to increased
mRNA expression levels [103] and to disease severity [19, 20].
In postmortem brain tissue studies, the 3󸀠 region SNPs
rs356219 [84], rs356165 [24], and rs11931074 [39] have been
associated with increased gene expression. For rs356219,
the heterozygote CT genotype correlated with higher levels
of SNCA-mRNA in the substantia nigra of PD patients.
However, the TT protective genotype was accompanied by
higher expression in the cerebellum, a structure that is more
preserved in the course of PD [84]. Similarly, G-rs356219
allele carriers presented higher levels of the SNCA112-mRNA
isoform in the frontal cortex [24]. Further, PD patients
presented higher levels of the SNCA-112 and SNCA-98 tran-
scripts in the cerebellum and occipital cortex when compared
to controls [39].
Linnertz et al. [104] investigated the effects of SNCASNPs
in 5󸀠 and 3󸀠 regions on SNCA expression in postmortem
brains from neurologically normal subjects. For REP1, the
256 bp/256 bp genotype correlated with lower SNCA-mRNA
levels, corroborating the hypotheses that decreased SNCA
levels protect against the disease.Unexpectedly, the protective
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genotypes AA-rs356219 and AA-rs365165 in the 3󸀠 region
correlatedwith higher levels of SNCA-mRNA in the temporal
cortex and substantia nigra, which highlights an expanded
regulatory effect of this region on total SNCA-mRNA levels.
Regarding in vivo studies, patients with SNP rs2583988
genotypes did not present alterations in alpha-synuclein lev-
els in peripheral blood mononuclear cells, while the protein
levels were reduced in the absence of the REP1 risk allele [84].
For SNPs in the 3󸀠 region, while carriers of T-rs11931074 allele
presented reduced levels of protein in serum [57], a higher
level of alpha-synuclein in plasma was observed in carriers of
the C-rs356219 allele [65].
7. Genetical Background, Ethnicity,
and the Effect of SNCA SNPs
Methodological aspects such as variations in the sample size,
control of population stratification, and statistical analyses
can explain the discrepancies in the effects of SNPs among
the different studies. In addition, it is common to exclude
the influence of confounder variables as sex, age, and ethnic
background, which can modify the results substantially.
The majority of the studies were carried out in countries
of Europe, North America, and Asia, that is, populations with
mainly Caucasian and Asian genetic backgrounds. Despite
the fact that ethnic differences can preclude the generalization
of the results in genetic studies, many of the SNPs showed
similar effects in groups with different genetic backgrounds.
For example, the SNP rs356219 remained an important risk
factor for PD in studies performed within North American
[65], Spanish [63], Russian [44], and Chinese [41] popu-
lations. Nevertheless, given the significance of results and
perspectives of clinical advancement, it seems necessary to
extend these investigations to other continents, in order
to confirm whether these genetic effects are consistent
across different populations and to verify the implications of
between-population heterogeneity.
Finally, apart from variants in the SNCA gene, it is nec-
essary to consider the role of interactions between multiple
genetic variants in disease risk and clinical profile. For
example, investigations of phenotypic diversity in PD have
identified an association between SNCA and MAPT. This
association contributed to increased cognitive and motor
severity in a Chinese sample [31] and influenced the devel-
opment of cognitive impairment and dementia in a British
sample [78]. In addition, polymorphisms in GAB [28] and
LRRK2 [58] have been associated with earlier age at the onset
in a European-American population and in a Spanish sam-
ple, respectively. Also, in North Americans, APOE variants
predicted lower cognitive performance in PD patients [42].
8. Conclusions
This review collected the contributions of polymorphisms in
the SNCA gene to PD susceptibility and clinical phenotypes.
In most of the studies, the influence of polymorphisms in
multiple regions of SNCA gene was pointed out, such as
the promoter region (REP1-SNCA), 3󸀠 end (e.g., rs11931074
and rs356219), 3󸀠 untranslated regions (e.g., rs356165), and
introns (e.g., rs7684318, rs894278, and rs276990). In addition,
we highlight that it is necessary to expand the clinical
applicability of these data, as well as investigate the role
of SNCA variations in populations with different ethnic
backgrounds.
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